BioGenix Secures $75M Series B Funding to Transform Regenerative Medicine with Umbilical Cord-Derived Therapies

BioGenix is proud to announce a groundbreaking funding milestone with the successful raise of $75,000,000, a move that will further accelerate its mission in regenerative medicine. Founded on the belief that patients suffering from past injuries, chronic conditions, or degenerative diseases deserve renewed hope, BioGenix has emerged as a pioneering force in the development of ethically sound, safe, and reliable regenerative products. The infusion of new capital will be strategically directed toward expanding research and development efforts, scaling up clinical trials, and enhancing the production of our innovative umbilical cord-derived products. By leveraging the robust medical advantages of growth-factor rich tissue, we are able to offer physicians across multiple specialty areas domestically and around the world a non-invasive alternative that avoids the pitfalls associated with traditional surgical procedures. Our journey began with a clear recognition of regenerative medicine’s transformative potential, and today, by working closely with hospitals engaged in umbilical cord tissue donation programs and collaborating with a trusted, sterile, FDA registered laboratory, we have transformed visionary concepts into life-changing treatments. The funding will also be used to solidify our partnerships, further streamline our tissue processing, and extend our reach into new international markets. With this capital boost, BioGenix is set to deepen its commitment to ethical practices and scientific innovation, fueling the next phase of growth that will empower patients, support healthcare professionals, and redefine possibilities in regenerative medicine. This landmark funding not only validates our revolutionary approach but also underscores our unwavering determination to deliver hope and healing through cutting-edge medical technology.